Profiling mTOR pathway in neuroendocrine tumors. (Q38034440)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22890559%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

title

Profiling mTOR pathway in neuroendocrine tumors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22890559%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22890559%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Sara Cingarlini

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22890559%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Vincenzo Corbo

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22890559%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Giampaolo Tortora

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22890559%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

author name string

M Bonomi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22890559%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

publication date

14 August 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22890559%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22890559%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22890559%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

page(s)

183-188

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22890559%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22890559%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11523-012-0226-9

11 February 2020

exact match

0 references

cites work

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0226-9

Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0226-9

The NF1 tumor suppressor critically regulates TSC2 and mTOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0226-9

Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0226-9

Loss of PTEN expression in neuroendocrine pancreatic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0226-9

Genetic differences in endocrine pancreatic tumor subtypes detected by comparative genomic hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0226-9

Chromosomal alterations detected by comparative genomic hybridization in nonfunctioning endocrine pancreatic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0226-9

Gene Amplifications in Well-Differentiated Pancreatic Neuroendocrine Tumors Inactivate the p53 Pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0226-9

DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0226-9

MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0226-9

Pancreatic endocrine tumours: mutational and immunohistochemical survey of protein kinases reveals alterations in targetable kinases in cancer cell lines and rare primaries

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0226-9

Everolimus for advanced pancreatic neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0226-9

Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0226-9

The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0226-9

Targeting the phosphoinositide 3-kinase pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0226-9

Phosphatidylinositol 3-kinase-Akt signaling in pulmonary carcinoid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0226-9

Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0226-9

PI3K signalling: the path to discovery and understanding.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0226-9

Perturbations of the AKT signaling pathway in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0226-9

Colorectal cancer: mutations in a signalling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0226-9

A new mutational AKTivation in the PI3K pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0226-9

AKT1(E17K) in human solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0226-9

Epidermal growth factor receptor expression and activation in neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0226-9

Perifosine-mediated Akt inhibition in neuroendocrine tumor cells: role of specific Akt isoforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0226-9

First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0226-9

New insights into mTOR signaling: mTORC2 and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0226-9

The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0226-9

Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0226-9

The PTEN-PI3K pathway: of feedbacks and cross-talks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0226-9

Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0226-9

Activating mutations of TOR (target of rapamycin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0226-9

The pharmacology of mTOR inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0226-9

Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0226-9

The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0226-9

Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0226-9

Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0226-9

PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0226-9

Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0226-9

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0226-9

MicroRNA Expression Abnormalities in Pancreatic Endocrine and Acinar Tumors Are Associated With Distinctive Pathologic Features and Clinical Behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0226-9

Targeting the PI3K/mTOR pathway in murine endocrine cell lines: in vitro and in vivo effects on tumor cell growth

21 January 2018

1 reference

12 December 2020

Activation of the serine/theronine protein kinase Akt in enteropancreatic neuroendocrine tumors.

1 reference

12 December 2020

AKT inhibition by triciribine alone or as combination therapy for growth control of gastroenteropancreatic neuroendocrine tumors

1 reference

12 December 2020

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

1 reference

12 December 2020